10x Genomics Inc Dossier
|
SectorHealth Care IndustryHealth Information Services Beta (adjusted)1.69 Intrinsic Value $36.07median of 3 methodsbased on filings through 30 Jun 2026 Market Price $90.36Price as of 30 Sep 2026 Significantly overvaluedIntrinsic value is 60% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-60%) Data confidence Sign in to view data confidence Market Cap $11.8B Enterprise Value $11.3B Shares Outstanding 129.5M diluted Moat Rating None Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary 10x Genomics remains the undisputed leader in single-cell biology and a dominant force in the rapidly growing spatial transcriptomics market. The company's business model is successfully transitioning toward high-margin, recurring consumables revenue, which now represents over 80% of total sales. This shift has significantly improved underlying profitability, as evidenced by gross margins expanding to 70% and a narrowing GAAP net loss in Q1 2026. However, near-term headwinds persist. Academic and translational research funding constraints continue to weigh heavily on instrument capital expenditures, leading to double-digit declines in instrument revenue. Furthermore, while the upcoming launch of the highly anticipated Atera platform represents a major technological leap, its commercial contribution will not materialize until late 2026 due to initial production capacity limits. At current valuation levels, the stock appears fully valued, reflecting a balanced risk-reward profile as the market adopts a wait-and-see approach regarding the Atera rollout and funding recovery. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$40.00 Mean target$49.54 High · most bullish analyst$65.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $40.00 Prolonged academic budget constraints and macroeconomic headwinds lead to deeper-than-expected declines in instrument placements. The commercial ramp of the Atera platform faces technical or manufacturing delays, causing customers to defer purchases further. Meanwhile, intense competition from consolidated players like Bruker (NanoString) pressures pricing on consumables, stalling gross margin expansion and delaying the company's path to profitability. Base CaseCentral scenario $49.54 Matches the consensus mean10x Genomics executes in line with its FY 2026 revenue guidance of $600 million to $625 million. Consumables revenue continues to grow at a double-digit pace, offsetting cyclical weakness in instrument sales. The Atera platform ships on schedule in the second half of the year but contributes minimally to FY 2026 financials due to early capacity constraints, setting up 2027 as the primary inflection year. Gross margins remain stable around 70%, and operating losses continue to narrow gradually. Bull CaseUpside scenario $65.00 The commercial launch of the Atera platform in H2 2026 exceeds expectations, driving a massive wave of preorders and rapid adoption of spatial whole-transcriptome analysis. Simultaneously, global academic and biopharmaceutical research funding rebounds sharply, unlocking pent-up demand for both Chromium and spatial instruments. Consumables volume growth accelerates into the high double digits, leading to operating leverage that pushes the company into sustained GAAP profitability ahead of schedule. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |